Earnings Releases·Nov 10, 2026, 8:03 AM ET

Tyra Biosciences — Third Quarter 2026 Earnings Summary

**Financial Performance:** Cash, cash equivalents, and marketable securities rose to $700.5 million as of September 30, 2026, from $255.0 million in December 2025, driven by a $400 million public offering completed in September 2026; net loss for the quarter was $51.1 million compared to $29.9 million in the prior year period, with total operating expenses for the nine months increasing to $145.9 million from $96.2 million.
**Capital Structure:** Total assets and stockholders' equity increased to $727.5 million and $692.8 million respectively as of September 30, 2026, up from $282.6 million and $259.2 million at the end of 2025, following the completion of the underwritten public offering led by RA Capital Management.
**Clinical Progress:** Initial Phase 2 results for SURF302 (IR NMIBC) reported a 79% overall response rate and 64% complete response rate at 60 mg QD with a favorable safety profile, while the Phase 3 adjuvant study is expected to initiate in 2027 subject to regulatory feedback.
**Future Outlook:** The company expects its current financial resources to fund operations through 2030, with additional Phase 2 data for IR NMIBC, LG-UTUC, and achondroplasia anticipated in 2027 as it advances preparations for registrational development and regulatory engagement.